GLP-1 therapies continue to reshape chronic disease treatment, triggering regulatory updates, new clinical findings and intensifying competition across the pharmaceutical market.
Here are three trends driving the drug class forward:
1. Regulatory momentum accelerates
On Jan. 13, the FDA directed drugmakers to remove suicidal ideation warnings from three GLP-1s — Saxenda, Wegovy and Zepbound — after reviewing 91 clinical trials and a retrospective cohort of 2.2 million patients. The agency found no elevated risk of psychiatric events, including among patients with obesity or Type 2 diabetes.
Meanwhile, the FDA and HHS cracked down on compounded GLP-1 pills. Telehealth firm Hims & Hers launched a compounded version of Novo Nordisk’s oral Wegovy Feb. 5, but reversed course two days later following legal threats from Novo Nordisk and a Justice Department referral. The FDA said it will restrict marketing of compounded GLP-1s as similar alternatives to approved drugs.
2. Oral GLP-1s drive growth — and legal risk
Novo Nordisk’s once-daily oral Wegovy could be the fastest pharmaceutical launch in U.S. history. IQVIA data show 26,100 prescriptions were written in the drug’s third week on the market, a 42% increase from the prior week. Healthcare investment banker Leerink Partners called it “the fastest drug launch ever.”
The rapid uptake comes amid escalating tensions between brand-name manufacturers and companies marketing compounded versions. In 2025, compounded GLP-1s made up nearly 30% of the U.S. market, prompting lawsuits and tighter FDA oversight. The next disruption could arrive in March, when the FDA is expected to decide on Eli Lilly’s competing oral GLP-1, orforglipron.
3. Evidence and adoption trends shift
A Jan. 20 study published in Annals of Internal Medicine found bariatric surgery outperformed GLP-1s in reducing A1C and weight among patients with Type 2 diabetes, regardless of social vulnerability. As GLP-1 prescriptions increased 132.6% between 2022 and 2023, bariatric surgery volumes declined 25.6%. Vizient projects an additional 15% decline in surgery volumes by 2034.
Prescribing trends are also shifting. In 2025, more than 500,000 clinicians wrote GLP-1 prescriptions, led by endocrinologists. Cardiologists and pediatricians were among the slowest adopters, according to IQVIA.
A separate cohort study of 550,000 patients, published Feb. 9 and conducted by George Washington University, found GLP-1 users had higher odds of nonscarring hair loss — including telogen effluvium and androgenetic alopecia — compared to matched controls. The risk appeared independent of weight loss and other clinical variables.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.